Upadacitinib for Refractory Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis-Related Interstitial Lung Disease
Cureus · 24.03.2026
DOI: 10.7759/cureus.105756 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 24.03.2026. Verfasst von Kohei Morikawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, Jichi Medical University Saitama Medical Center, Saitama, JPN. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Medicine, Jichi Medical University Saitama Medical Center, Saitama, JPN.
- Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Shimotsuke, JPN.
- Department of Rheumatology, Aomori Prefectural Central Hospital, Aomori, JPN.
Zitieren
APA
Morikawa, K., Nagashima, T., Yabe, H., & Kanazawa, H. (2026). Upadacitinib for Refractory Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis-Related Interstitial Lung Disease. Cureus. https://doi.org/10.7759/cureus.105756
Vancouver
Morikawa K, Nagashima T, Yabe H, Kanazawa H. Upadacitinib for Refractory Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis-Related Interstitial Lung Disease. Cureus. 2026. doi:10.7759/cureus.105756
BibTeX
@article{Morikawa2026,
author = {Morikawa, Kohei and Nagashima, Takao and Yabe, Hiroki and Kanazawa, Hiroshi},
title = {Upadacitinib for Refractory Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis-Related Interstitial Lung Disease},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.105756}
}
EUVIMED